



PHOGEN LTD

Business Offices, 155 Cambridge Science Park
Cambridge CB4 4GN
UK

Telephone

+44 (0) 1223 424488

Fax

+44 (0) 1223 426115

E-mail

business@phogen.com

Web Site

www.phogen.com

Contact Person

Dr Elizabeth Rollinson – Managing Director

Technology Specialisations

Independently published data in animal models show that Phogen's proprietary VP22 gene technology greatly enhances the immunogenicity of DNA vaccines (CTL responses 50-fold), and the therapeutic efficacy of other gene-based products (10-fold). In addition, Phogen's Vectosome technology has been shown both *in vitro* and *in vivo* to provide a highly effective intracellular/intranuclear delivery system for a variety of therapeutic moieties, including proteins/peptides, genes/antisense oligonucleotides/siRNA and small molecules. Vectosomes have particular utility in providing efficient, non-toxic delivery that can usefully be aimed at selected cell populations.

The key benefits of VP22 include enhancement of efficacy and safety as well as a favourable impact on cost of goods and manufacturing scale. The applications of VP22 technology encompass the fields of human therapeutics, particularly vaccines and oncology, as well as animal health, functional genomics, target validation and diagnostics, and potentially plant biotechnology.

Corporate Relationships Sought

Are you looking to enhance the delivery, efficacy and/or safety of your therapeutic entity, or would the readout from your cell-based screens benefit from a non-toxic and selective delivery system that reduces background 'noise'? Phogen's VP22 technology could provide the solution you need, and the Company is thus seeking collaboration and licensing opportunities across the many applications of VP22. Strategic M&A opportunities will also be pursued.